Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription


6 AJR Am J Roentgenol
11 Anticancer Res
6 BMC Cancer
4 Br J Cancer
3 Breast Cancer
2 Breast Cancer (Dove Med Press)
5 Breast Cancer Res
7 Breast Cancer Res Treat
7 Cancer
3 Clin Breast Cancer
2 Clin Cancer Res
1 Clin Exp Metastasis
1 Clin Med Insights Oncol
1 Discov Oncol
1 Gene
1 Int J Cancer
2 J Clin Oncol
2 J Surg Oncol
2 Lancet
1 Mod Pathol
1 NPJ Breast Cancer
4 PLoS One
1 Radiology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. DONTCHOS BN, Rahbar H
    Cost-Effectiveness of Breast Cancer Staging Modalities: Counterpoint-Breast MRI Can be Cost-Effective for Breast Cancer Staging, Particularly in This Era of Treatment De-Escalation.
    AJR Am J Roentgenol. 2023 Apr 26. doi: 10.2214/AJR.23.29501.

  2. LOBBES MBI, Essers BAB
    Cost-Effectiveness of Breast Cancer Staging Modalities: Point-Contrast-Enhanced Mammography as an Alternative to Breast MRI for Preoperative Staging in Patients with Breast Cancer.
    AJR Am J Roentgenol. 2023 Apr 26. doi: 10.2214/AJR.23.29337.

    Editorial Comment: Abbreviated MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment-One Step Forward in an Important Research Pathway.
    AJR Am J Roentgenol. 2023 Feb 22:9. doi: 10.2214/AJR.23.29167.

  4. OFFIT LR, Chikarmane SA, Lacson RC, Giess CS, et al
    Frequency and Outcomes of BI-RADS Category 3 Assessments in Patients With a Personal History of Breast Cancer: Full-Field Digital Mammography Versus Digital Breast Tomosynthesis.
    AJR Am J Roentgenol. 2023 Apr 12. doi: 10.2214/AJR.23.29067.
    PubMed         Abstract available

  5. SEILER SJ, Neuschler EI, Butler RS, Lavin PT, et al
    Optoacoustic Imaging With Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study.
    AJR Am J Roentgenol. 2022 Dec 7. doi: 10.2214/AJR.22.28470.
    PubMed         Abstract available

  6. OLUYEMI ET, Ambinder EB
    Beyond the AJR: Racial and Ethnic Disparities in the Timeliness of Biopsy After Abnormal Screening Mammography.
    AJR Am J Roentgenol. 2022 Sep 7. doi: 10.2214/AJR.22.28458.

    Anticancer Res

  7. PARK NR, Lee YJ, Lee SH, Kim JE, et al
    Anti-cancer Effect of Unique Cartilage Matrix-associated Protein in Breast Cancer Cells Depends on gamma-Carboxylation.
    Anticancer Res. 2023;43:1959-1965.
    PubMed         Abstract available

  8. KIM YJ, Jang SK, Kim G, Hong SE, et al
    Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors.
    Anticancer Res. 2023;43:1973-1980.
    PubMed         Abstract available

  9. KIM EY, Ahn S
    Epithelial-mesenchymal Transition Factor and Its Association With Mammographic Density and Breast Cancer Prognosis.
    Anticancer Res. 2023;43:2281-2292.
    PubMed         Abstract available

  10. MEUCCI R, Buonomo OC, Perretta T, Manenti G, et al
    Vacuum-assisted Evacuation (VAEv) of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries and Percutaneous Procedures.
    Anticancer Res. 2023;43:2135-2143.
    PubMed         Abstract available

  11. YAMANAKA T, Oshima T, Murayama D, Okamoto S, et al
    Clinical Significance of Cancer Stem Cell Markers in Primary and Metastatic Tissues in Patients With Breast Cancer.
    Anticancer Res. 2023;43:2145-2154.
    PubMed         Abstract available

  12. GOSSET M, Gal J, Schiappa R, Helwig C, et al
    Breast Cancer and SARS-Cov2: Lessons from a Pandemic.
    Anticancer Res. 2023;43:2235-2241.
    PubMed         Abstract available

  13. ZWICKER F, Klepper R, Hauswald H, Hoefel S, et al
    Helical Tomotherapy of Lymph Node-negative Early-stage Breast Cancer After Breast-conserving Surgery: Long-term Results.
    Anticancer Res. 2023;43:2041-2053.
    PubMed         Abstract available

  14. OMORI S, Shigechi T, Kawaguchi K, Ijichi H, et al
    Successful Prevention of Tumour Lysis Syndrome in HER2-positive Breast Cancer: Case Report and Literature Review.
    Anticancer Res. 2023;43:2371-2377.
    PubMed         Abstract available

  15. MIYASAKA Y, Yoshimoto Y, Ando K, Murata K, et al
    CD8-positive Tumor-infiltrating Lymphocytes and Prognosis in Radiotherapy for Uterine Cervical Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:2077-2084.
    PubMed         Abstract available

  16. CHU J, Kim HS, DO SI
    Clinicopathological Significance and Predictive Value of High Intratumoral Tumor Budding in Patients With Breast Carcinoma Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2023;43:2323-2332.
    PubMed         Abstract available

  17. SUSINI T, Nesi I, Renda I, Giani M, et al
    Reducing the Use of Frozen Section for Sentinel Node Biopsy in Breast Carcinoma: Feasibility and Outcome.
    Anticancer Res. 2023;43:2161-2170.
    PubMed         Abstract available

    BMC Cancer

  18. AN Y, Fnu G, Xie C, Weber GF, et al
    Meta-analysis of Osteopontin splice variants in cancer.
    BMC Cancer. 2023;23:373.
    PubMed         Abstract available

  19. ZHANG W, Lin S, Zeng B, Chen X, et al
    High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients.
    BMC Cancer. 2023;23:377.
    PubMed         Abstract available

  20. HAYAMA S, Nakamura R, Ishige T, Sangai T, et al
    The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
    BMC Cancer. 2023;23:384.
    PubMed         Abstract available

  21. DAI X, Cai L, Zhang Z, Li J, et al
    SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity.
    BMC Cancer. 2023;23:376.
    PubMed         Abstract available

  22. POMEY MP, Nelea MI, Normandin L, Vialaron C, et al
    An exploratory cross-sectional study of the effects of ongoing relationships with accompanying patients on cancer care experience, self-efficacy, and psychological distress.
    BMC Cancer. 2023;23:369.
    PubMed         Abstract available

  23. BASSI N, Hovland HN, Rasheed K, Jarhelle E, et al
    Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays.
    BMC Cancer. 2023;23:368.
    PubMed         Abstract available


  24. GATHANI T, Cutress R, Horgan K, Kirwan C, et al
    Age and sex can predict cancer risk in people referred with breast symptoms.
    BMJ. 2023;381:e073269.

    Br J Cancer

  25. GARETH EVANS D, McWilliams L, Astley S, Brentnall AR, et al
    Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).
    Br J Cancer. 2023 Apr 24. doi: 10.1038/s41416-023-02273.

  26. KETCHEMEN JP, Babeker H, Tikum AF, Nambisan AK, et al
    Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics.
    Br J Cancer. 2023 Apr 24. doi: 10.1038/s41416-023-02272.
    PubMed         Abstract available

  27. LLOYD R, Pirikahu S, Walter J, Cadby G, et al
    Alternative methods to measure breast density in younger women.
    Br J Cancer. 2023;128:1701-1709.
    PubMed         Abstract available

  28. FRANKEN A, Kraemer A, Sicking A, Watolla M, et al
    Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value.
    Br J Cancer. 2023;128:1742-1752.
    PubMed         Abstract available

    Breast Cancer

  29. TOMIOKA N, Hatanaka KC, Okuyama D, Watanabe KI, et al
    Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Breast Cancer. 2023 Apr 27. doi: 10.1007/s12282-023-01454.

  30. JIAO Y, Guo X, Lv Q
    Options of locoregional therapy for primary foci of breast cancer influence the rate of nonregional lymph node metastasis in N2-N3 status patients: a SEER database analysis.
    Breast Cancer. 2023 Apr 27. doi: 10.1007/s12282-023-01459.
    PubMed         Abstract available

  31. LI JJ, Yu Y, Ge J
    HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Breast Cancer. 2023;30:364-378.
    PubMed         Abstract available

    Breast Cancer (Dove Med Press)

  32. MISKEEN E, Al-Shahrani AM
    Breast Cancer Awareness Among Medical Students, University of Bisha, Saudi Arabia.
    Breast Cancer (Dove Med Press). 2023;15:271-279.
    PubMed         Abstract available

  33. WANG J, Liao D, Zhang X, Miao C, et al
    Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review.
    Breast Cancer (Dove Med Press). 2023;15:281-294.
    PubMed         Abstract available

    Breast Cancer Res

  34. COHEN SY, Stoll CR, Anandarajah A, Doering M, et al
    Modifiable risk factors in women at high risk of breast cancer: a systematic review.
    Breast Cancer Res. 2023;25:45.
    PubMed         Abstract available

  35. ARYANNEJAD A, Saeedi Moghaddam S, Mashinchi B, Tabary M, et al
    National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019.
    Breast Cancer Res. 2023;25:47.
    PubMed         Abstract available

  36. ZHANG J, Qin Z, So TH, Chang TY, et al
    Acupuncture for chemotherapy-associated insomnia in breast cancer patients: an assessor-participant blinded, randomized, sham-controlled trial.
    Breast Cancer Res. 2023;25:49.
    PubMed         Abstract available

  37. RAGU ME, Lim JMC, Ng PS, Yip CH, et al
    TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.
    Breast Cancer Res. 2023;25:48.
    PubMed         Abstract available

  38. LEE S, Toft NJ, Axelsen TV, Espejo MS, et al
    Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer.
    Breast Cancer Res. 2023;25:46.
    PubMed         Abstract available

    Breast Cancer Res Treat

  39. DONAHUE PMC, MacKenzie A, Filipovic A, Koelmeyer L, et al
    Advances in the prevention and treatment of breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2023 Apr 27. doi: 10.1007/s10549-023-06947.
    PubMed         Abstract available

  40. ISAKOFF SJ, Said MR, Kwak AH, Glieberman E, et al
    Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study).
    Breast Cancer Res Treat. 2023 Apr 27. doi: 10.1007/s10549-023-06918.
    PubMed         Abstract available

  41. KIM SY, Choi Y, Kim YS, Ha SM, et al
    Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients.
    Breast Cancer Res Treat. 2023 Apr 25. doi: 10.1007/s10549-023-06952.
    PubMed         Abstract available

  42. DIBBLE KE, Deng Z, Connor AE
    Differences in survivorship care experiences among older breast cancer survivors by clinical cancer characteristics, race/ethnicity, and socioeconomic factors: A SEER-CAHPS study.
    Breast Cancer Res Treat. 2023 Apr 24. doi: 10.1007/s10549-023-06948.
    PubMed         Abstract available

  43. GRECO G, Bickell NA, Lin S, Yagnik R, et al
    Subjective social status, race, and metabolic syndrome in women with breast cancer.
    Breast Cancer Res Treat. 2023 Apr 23. doi: 10.1007/s10549-023-06949.
    PubMed         Abstract available

  44. DALY MB, Rosenthal E, Cummings S, Bernhisel R, et al
    The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
    Breast Cancer Res Treat. 2023 Apr 21. doi: 10.1007/s10549-023-06946.
    PubMed         Abstract available

  45. XU C, Wang Y, Hong Y, Yao R, et al
    Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.
    Breast Cancer Res Treat. 2023 Apr 21. doi: 10.1007/s10549-023-06931.
    PubMed         Abstract available


  46. LEHRER S, Rheinstein PH
    Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10.
    Cancer. 2023 Apr 27. doi: 10.1002/cncr.34828.

  47. LASHEN AG, Toss MS, Rakha EA
    Reply to "Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10%".
    Cancer. 2023 Apr 27. doi: 10.1002/cncr.34826.

  48. MANDELBLATT JS, Small BJ, Zhou X, Nakamura ZM, et al
    Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34784.
    PubMed         Abstract available

  49. CONROY SM, Von Behren J, Kwan ML, Kushi LH, et al
    Neighborhood attributes and cardiovascular disease risk in breast cancer survivors: The Pathways Study.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34794.
    PubMed         Abstract available

  50. SPENCER JC, Noel L, Shokar NK, Pignone MP, et al
    Understanding the role of access in Hispanic cancer screening disparities.
    Cancer. 2023;129:1569-1578.
    PubMed         Abstract available

  51. LU X, He M, Yu L, Gou Z, et al
    Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?
    Cancer. 2023;129:1492-1501.
    PubMed         Abstract available

  52. MANDELBLATT JS, Ruterbusch JJ, Thompson HS, Zhou X, et al
    Association between major discrimination and deficit accumulation in African American cancer survivors: The Detroit Research on Cancer Survivors Study.
    Cancer. 2023;129:1557-1568.
    PubMed         Abstract available

    Clin Breast Cancer

  53. JORGENSEN MG, Gozeri E, Petersen TG, Sorensen JA, et al
    Surgical-Site Infection is Associated With Increased Risk of Breast Cancer-Related Lymphedema: A Nationwide Cohort Study.
    Clin Breast Cancer. 2023 Apr 5:S1526-8209(23)00085.
    PubMed         Abstract available

  54. WILLERS N, Neven P, Floris G, Colpaert C, et al
    The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study.
    Clin Breast Cancer. 2023 Mar 22:S1526-8209(23)00075.
    PubMed         Abstract available

  55. HUANG X, Lin D, Lin S, Luo S, et al
    Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
    Clin Breast Cancer. 2023 Mar 31:S1526-8209(23)00082.
    PubMed         Abstract available

    Clin Cancer Res

  56. DISIS ML, Dang Y, Coveler AL, Childs JS, et al
    A Phase I/II trial of HER-2/neu vaccine primed autologous T-cell infusions in patients with treatment refractory HER-2/neu overexpressing breast cancer.
    Clin Cancer Res. 2023 Apr 24:CCR-22-3578. doi: 10.1158/1078-0432.CCR-22-3578.
    PubMed         Abstract available

  57. GIBSON CJ, Fell GG, Sella T, Sperling AS, et al
    Clonal Hematopoiesis in Young Women Treated for Breast Cancer.
    Clin Cancer Res. 2023 Apr 28:CCR-23-0050. doi: 10.1158/1078-0432.CCR-23-0050.
    PubMed         Abstract available

    Clin Exp Metastasis

  58. NAGTEGAAL ID, Snoek JAA, Bult P, Tol J, et al
    The value of case reports in rare oncological scenarios: mixed method analysis of colorectal metastases from breast cancer.
    Clin Exp Metastasis. 2023 Apr 27. doi: 10.1007/s10585-023-10207.
    PubMed         Abstract available

    Clin Med Insights Oncol

  59. LIANG T, Wu X, Wang L, Song T, et al
    Correlation of NNMT and DKK1 Protein Expression With Clinicopathological Characteristics and Prognosis of Breast Cancer.
    Clin Med Insights Oncol. 2023;17:11795549231168073.
    PubMed         Abstract available

    Discov Oncol

  60. SHI Z, Liu Y, Zhang S, Cai S, et al
    Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
    Discov Oncol. 2023;14:49.
    PubMed         Abstract available


  61. GHULE PN, Boyd JR, Kabala F, Fritz AJ, et al
    Spatiotemporal higher-order chromatin landscape of human histone gene clusters at Histone Locus Bodies during the cell cycle in breast cancer progression.
    Gene. 2023 Apr 22:147441. doi: 10.1016/j.gene.2023.147441.
    PubMed         Abstract available

    Int J Cancer

  62. KANNAN S, Cheng VWT
    Nanoparticle drug delivery to target breast cancer brain metastasis: Current and future trends.
    Int J Cancer. 2023 Apr 25. doi: 10.1002/ijc.34542.
    PubMed         Abstract available

    J Clin Oncol

  63. VACHON CM, Scott CG, Norman AD, Khanani SA, et al
    Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer.
    J Clin Oncol. 2023 Apr 27:JCO2201153. doi: 10.1200/JCO.22.01153.
    PubMed         Abstract available

  64. ROYCE M, Mulkey F, Osgood C, Bloomquist E, et al
    US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.
    J Clin Oncol. 2023 Apr 27:JCO2300615. doi: 10.1200/JCO.23.00615.

    J Surg Oncol

  65. HOSEIN S, Drebin HM, Kurtansky NR, Olofsson Bagge R, et al
    Are the MIA and MSKCC nomograms useful in selecting patients with melanoma for sentinel lymph node biopsy?
    J Surg Oncol. 2023 Mar 11. doi: 10.1002/jso.27231.
    PubMed         Abstract available

  66. RUBENSTEIN RN, Tadros A, Slutsky HL, Plotsker EL, et al
    Increasing rates of general anesthesia use in lumpectomy procedures: A 15-year trends analysis.
    J Surg Oncol. 2023;127:1092-1102.
    PubMed         Abstract available


    Advancing outcomes of metastatic HER2-positive breast cancer.
    Lancet. 2023 Apr 19:S0140-6736(23)00805-X. doi: 10.1016/S0140-6736(23)00805.

  68. ANDRE F, Hee Park Y, Kim SB, Takano T, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Apr 19:S0140-6736(23)00725-0. doi: 10.1016/S0140-6736(23)00725.
    PubMed         Abstract available

    Mod Pathol

  69. YEONG J, Goh D, Tan TJ, Tan B, et al
    Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression.
    Mod Pathol. 2023;36:100056.
    PubMed         Abstract available

    NPJ Breast Cancer

  70. ZHOU D, Li M, Yasin MH, Lu Q, et al
    The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer.
    NPJ Breast Cancer. 2023;9:30.
    PubMed         Abstract available

    PLoS One

  71. BO MC, Merlo A, Ligabue MB, Bassi MC, et al
    Self-managed physical activity in breast cancer survivors: A scoping review.
    PLoS One. 2023;18:e0284807.
    PubMed         Abstract available

  72. WESTERN B, Demmelmaier I, Vistad I, Hansen BH, et al
    How many days of continuous physical activity monitoring reliably represent time in different intensities in cancer survivors.
    PLoS One. 2023;18:e0284881.
    PubMed         Abstract available

  73. CARVALHO SM, Andrade CA, Ferreira MBLS, de Souza KSS, et al
    Women's perception about the discovery of breast cancer amid the covid-19 pandemic.
    PLoS One. 2023;18:e0282610.
    PubMed         Abstract available

  74. LLANO-LEON M, Martinez-Enriquez LC, Rodriguez-Bohorquez OM, Velandia-Vargas EA, et al
    Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysis.
    PLoS One. 2023;18:e0277714.
    PubMed         Abstract available


  75. CONANT EF, Talley MM, Parghi CR, Sheh BC, et al
    Mammographic Screening in Routine Practice: Multisite Study of Digital Breast Tomosynthesis and Digital Mammography Screenings.
    Radiology. 2023 Mar 14:221571. doi: 10.1148/radiol.221571.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.